Table 32Adjusted indirect analysis of risk of depression with interferon use

ComparisonRelative risk (95% CI)
Interferon β-1b SC (Betaseron®) vs. interferon β-1a SC (Rebif®) 44μg0.74 (0.401 to 1.36)
Interferon β-1b SC (Betaseron®) vs. interferon β-1a IM (Avonex®)0.79 (0.42 to 1.48)
Interferon β-1a SC (Rebif®) 44 μg vs. interferon β-1a IM (Avonex®)1.05 (0.68 to 1.63)

Abbreviations: SC, subcutaneous.

From: Results

Cover of Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].
Smith B, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2010 Aug.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.